ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)

Market Cap	5.10B -20.8%
Revenue (ttm)	801.40M +49.4%
Net Income	177.17M +119.6%
EPS	0.80 +118.2%
Shares Out	220.34M
PE Ratio	28.93
Forward PE	24.74
Dividend	0.25 (1.08%)
Ex-Dividend Date	Jun 5, 2026

Volume	5,450,507
Open	23.42
Previous Close	23.33
Day's Range	22.73 - 23.98
52-Week Range	20.91 - 34.26
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About ChengDu ShengNuo Biotec

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. It provides semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. ChengDu Sh...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,605
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688117

Financial Performance

In 2025, ChengDu ShengNuo Biotec's revenue was 741.46 million, an increase of 62.57% compared to the previous year's 456.07 million. Earnings were 157.92 million, an increase of 215.70%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 29, 2026

Data Sources Report a data error